Start Time: 16:30 January 1, 0000 5:03 PM ET

BioRestorative Therapies, Inc. (NASDAQ:BRTX)
Q2 2024 Earnings Conference Call
August 13, 2024, 16:30 PM ET

Company Participants

Lance Alstodt - President, CEO and Chairman
Robert Kristal - CFO
Francisco Silva - VP, R&D
Stephen Kilmer - Head of IR

Conference Call Participants

Jonathan Aschoff - ROTH MKM
Michael Okunewitch - The Maxim Group
Elemer Piros - Rodman and Renshaw

Operator

Good afternoon, and welcome to the BioRestorative Therapies Second Quarter 2024 Investor Call. At this time, all participants are in a listen-only mode and we will open for questions following the presentation. [Operator Instructions]. Please note this conference is being recorded.

I will now turn the conference over to your host, Stephen Kilmer, Investor Relations. Stephen, the floor is yours.

Stephen Kilmer

Thank you. Good afternoon, everyone. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are based on BioRestorative Therapies' current beliefs, assumptions and expectations, and such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. No forward-looking statement can be guaranteed.

For details on factors, among others, that could affect expectations, see Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission. Listeners are cautioned not to place undue reliance on these forward-looking statements. We speak only as of the date of this conference call. BioRestorative undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, other than as required by law.

On the call today representing the company are Lance Alstodt, BioRestorative's Chairman and Chief Executive Officer; Francisco Silva, our Vice President of Research and Development; and Robert Kristal, the company's Chief Financial Officer.

With that said, I'll now turn the call over to Lance.

Lance Alstodt

Thank you, Steve, and good afternoon, everyone. Welcome to our second quarter quarterly conference call. On behalf of the management team and everyone at BioRestorative, I'd like to thank you for your interest in our company. And for those of you who are shareholders, we appreciate your support.

We've had a very interesting and very productive first half of 2024. We're energized by the many potential value-enhancing inflection points that we see ahead. As you can see from the financial results we announced today, we're very pleased with our quarterly and first half success. The team has executed well on all of our programs, and with the commencement of our commercial platform and the execution of the Cartessa contract, we are also starting to make progress on a path to sustainable profitability.